Press Releases

Arch Therapeutics Receives Marketing Clearance from the US FDA Related to the AC5® Topical Gel Supply Chain
Arch Therapeutics, Inc. to Present at the New York City based Investor Summit on March 25th-26th
Arch Therapeutics Novel Self-Assembling Agent for Use in Endoscopic Procedures to be Presented at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) 2020 Annual Meeting on April 2, 2020
Arch Therapeutics to Provide Corporate Update at the 2020 LD Micro Virtual Investor Conference
Arch Therapeutics to Provide Corporate Update at Biotech Showcase™ 2020 on January 13th, 2020
Arch Therapeutics Announces $2.5 Million Registered Direct Offering
Arch Therapeutics Provides Corporate Update at the 2nd Annual LD Micro Big Apple Conference in Manhattan, NY
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 21st Annual Global Investment Conference
Arch Therapeutics Announces AC5 Self-Assembling Peptide Technology Platform Demonstrates Antimicrobial Activity in Two Studies and Provides CE Marking Status Update for AC5™ Topical Hemostat
Arch Therapeutics to Provide Corporate Update at the 9th Annual LD Micro Invitational
Arch Therapeutics, Inc. $2.8 Million Registered Direct Offering
Arch Therapeutics Announces Attendance at 2019 Symposium on Advanced Wound Care Conference (SAWC) and Release of a New AC5TM Topical Gel Video
Arch Therapeutics to Provide Corporate Update at the 31st Annual ROTH Conference
Arch Therapeutics to Provide Corporate Update at the 2019 BIO CEO & Investor Conference
Arch Therapeutics to Provide Corporate Update at the 11th Annual Biotech Showcase™ 2019 Conference on January 8th, 2019
Arch Therapeutics Receives 510(k) Clearance from the US FDA for AC5™ Topical Gel
Arch Therapeutics Provided Corporate Update at the 11th Annual LD Micro Main Event
Arch Therapeutics Announces Positive Outcome of Ruling from Japanese Intellectual Property High Court
Arch Therapeutics Announces Submission of CE Mark File for AC5™ Topical Hemostat in Europe
Arch Therapeutics to Provide Corporate Update at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5™ Topical Gel
Arch Therapeutics to Provide Corporate Update at the Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018
Arch Therapeutics Reports Topline Results from Skin Sensitization Study of AC5
Arch Therapeutics to Provide Corporate Update at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018
Arch Therapeutics Announces Poster Presentation at the 2018 Military Health System Research Symposium on Tuesday, August 21, 2018
Arch Therapeutics Appoints Healthcare Industry Executive Punit Dhillon to Board of Directors
Arch Therapeutics, Inc. $4.5 Million Registered Direct Offering
Arch Therapeutics Provides Skin Sensitization Study Status Update
Arch Therapeutics Completes Enrollment and Initiates Dosing in Skin Sensitization Study
Arch Therapeutics to Provide Corporate Update at the 8th LD Micro Invitational on Monday, June 4, 2018
Arch Therapeutics Provides Update on Study Initiation and 510(k)
Arch Therapeutics Provides Update on 510(k)
Arch Therapeutics to Provide Corporate Update at the 30th Annual Roth Conference on March 12, 2018
Dermatologic Surgery Publishes Clinical Data on Arch Therapeutics’ AC5™ in a Topical Application
Arch Therapeutics to Provide Corporate Update at The 10th Annual Biotech Showcase™ 2018 Conference on January 8th, 2018
Arch Therapeutics Withdraws 510(k) with Plans to Resubmit After Further Discussions with FDA
Arch Therapeutics to Provide Corporate Update at the 10th Annual LD Micro Main Event In Los Angeles December 5-7, 2017
Arch Therapeutics to Provide Corporate Updates at Upcoming Industry and Investment Conferences
Arch Therapeutics Reports Favorable Results in Repeat Dose Testing of AC5™ for Subchronic Systemic Toxicity
Arch Therapeutics to Provide Corporate Update at the 19th Annual Rodman & Renshaw Global Investment Conference In New York City September 10-12, 2017
Arch Therapeutics Announces 510(k) Submission to the U.S. FDA for AC5(TM) Topical Gel
Arch Therapeutics Presents Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
Arch Therapeutics to Provide Corporate Update at the LD Micro Invitational on Tuesday, June 6, 2017
Arch Therapeutics to Provide Corporate Update at the 29th Annual Roth Conference on Monday, March 13, 2017
Arch Therapeutics to Provide Corporate Update at the Maxim Group - Haitong Securities Healthcare Investor and Partnering Conference
Arch Therapeutics, Inc. $6.1 Million Registered Direct Offering
Arch Therapeutics Provides Corporate Milestone Update, Including Anticipated Filing of 510(k) for AC5(TM)
Arch Therapeutics to Provide Corporate Updates at Two Conferences in New York, February 2017
Arch Therapeutics Announces Issuance of Method-of-Use Patent Covering Self-Assembling Peptidomimetics
Arch Therapeutics to Present at Noble Financial Capital Markets' Thirteenth Annual Equity Conference
Arch Therapeutics to Present at The Biotech Showcase(TM) 2017 Conference on January 10th, 2017
Arch Therapeutics to Present at 9th Annual LD Micro Main Event on December 7, 2016
Arch Therapeutics Reports AC5 Topical Hemostatic Device Successfully Stopped Bleeding in Patients on Antiplatelet Therapy in Recently Completed Clinical Study
Arch Therapeutics Will Present at the 2016 Bio Investor Forum in San Francisco, California October 18-19th, 2016
Arch Therapeutics Will Present at the 2016 Aegis Capital Growth Conference in Las Vegas, NV September 20-22, 2016
Arch Therapeutics Provides Corporate Update at the 18th Annual Rodman & Renshaw Global Investment Conference
Arch Therapeutics Will Present 18th Annual Rodman & Renshaw Global Investment Conference in New York City September 11-13th, 2016
Arch Therapeutics' President and CEO, Terrence Norchi, MD, Featured on "Small Cap Spotlight" Podcast Broadcasted Globally on Publicwire
Arch Therapeutics Reports AC5 Topical Hemostatic Device Meets Primary and Secondary Endpoints in First Clinical Study
Arch Therapeutics Completes Patient Enrollment in Clinical Study of AC5
Arch Therapeutics Announces May 26, 2016 $3.4 Million Private Placement
Arch Therapeutics Announces Issuance of Composition of Matter Patent Covering Self-Assembling Peptidomimetics
Arch Therapeutics Receives Notice of Allowance for Composition of Matter and Method of Use Patent Covering Solid Forms of Self-Assembling Peptides
Arch Therapeutics to Present at PIONEERS 2016 by Joseph Gunnar & Co. Thursday, May 5, 2016
Arch Therapeutics Receives Notice of Allowance for Patent Covering Systemic Applications for Self-Assembling Peptides
Arch Therapeutics Announces Notice of Allowance for Method of Use Patent Covering Uses of Self-Assembling Peptides
Arch Therapeutics Announces Notice of Allowance for Composition-of-Matter Patent Covering Self-Assembling Peptides
Arch Therapeutics Obtains Favorable Safety Data for AC5 Surgical Hemostatic Device(TM) in Skin Irritation Testing in Humans
Arch Therapeutics Reports Favorable Results for AC5 Surgical Hemostatic Device in Biocompatibility Testing Required for CE Mark
Arch Therapeutics to Present at the 28th Annual Roth Capital Conference on Tuesday, March 15, 2016
Arch Therapeutics Receives ISO 13485 Certification for AC5
Arch Therapeutics Clinical Trial Actively Enrolling Patients and Providing Investigational Treatment
Arch Therapeutics to Present at the SeeThruEquity Annual Innovations Investor Conference in Miami, Florida on Monday, February 22, 2016
Arch Therapeutics to Present at the Source Capital Group's 2016 Disruptive Growth & Healthcare Conference on Wednesday, February 10, 2016
Arch Therapeutics to Present at the BIO CEO & Investor Conference on Monday, February 8, 2016
Arch Therapeutics to Present at the Biotech Showcase(TM) 2016 Conference on January 12th 2016
RSS